Browse studies

Find your next paid study

101 recruiting studies matching your filters

Mechanism of HA35 in Patients With Alcoholic Liver Disease

Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 d…

Alcoholic Hepatitis

Estimated

~$10 – $6,250

The Cleveland ClinicNCT05018481

Phase 3

A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and…

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Estimated

~$10 – $8,750

Altimmune, Inc.NCT07795164

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to N…

NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$10 – $8,750

Akero Therapeutics, IncNCT06528314

Phase 2

GU-228: Mycophenolate Mofetil in Combination With Prednisone as First-line Treatment of Immune Related Hepatitis Resulting From Checkpoint Inhibitor Therapy

This phase II study evaluates whether early treatment with mycophenolate mofetil (MMF) plus prednisone improves liver inflammation caused by immune checkpoint …

Immune-mediated HepatitisImmune-related Adverse Event

Estimated

~$10 – $6,250

Fox Chase Cancer CenterNCT07663422

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO…

Alcoholic HepatitisAlcohol-related Liver Disease

Estimated

~$10 – $1,050

HepQuant, LLCNCT07060547

Observational

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES)

This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote con…

Colorectal Cancer ScreeningHepatitis C Virus

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT06745895

Phase 2

A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Resmetirom in Pediatric Subjects Ages 6-17 Years With MASH With Fibrosis Stage F1-F3

This study will evaluate the safety, pharmacokinetics (how the body absorbs, distributes, metabolizes, and eliminates the drug), and pharmacodynamics (how the …

MASHMASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$10 – $8,750

Madrigal Pharmaceuticals, Inc.NCT07763015

Phase 2

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a THRβ Agonist (ECC4703), an SSAO Inhibitor (ECC0509), and Their Combination in Adults With Presumed MASH

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and …

Metabolic Dysfunction-associated Steatohepatitis

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adul…

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Estimated

~$10 – $8,750

89bio, Inc.NCT06318169

Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis st…

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

Estimated

~$10 – $8,750

89bio, Inc.NCT06419374

Phase 1

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of VV-14303, an Adeno-associated Virus Vector-mediated Fibroblast Growth Factor 21 (FGF21) Gene Therapy, in Adults With Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Estimated

~$10 – $8,750

Kriya Therapeutics, Inc.NCT07732400

Phase 4

AI-Powered Hepatitis C Single-Encounter Test-and-Treat

This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will rece…

HEPATITIS C (HCV)

Estimated

~$10 – $7,500

Patrick GraceNCT07793643